A compound selected from those of formula (I): ##STR1##

wherein

W₁ represents O, S, or —NR₃ in which R₃ represents hydrogen, alkyl, OH or CN;

W₂ represents a group selected from hydrogen, CF₃, NH₂, monoalkylamino, dialkylamino, alkyl, alkenyl, alkynyl, aryl, arylalkyl, cycloalkylalkyl, heterocycle, these groups being optionally substituted,

or W₁ and W₂ form together a group of formula —NX₄—W₃— as defined in the description,

X₁, X₂ and X₃ represent N or C optionally substituted,

n is 0 to 8,

Z represents —CR₁₂R₁₃, wherein R₁₂ and R₁₃ are as defined in the description,

A represents a ring system,

the groups R₂ represent hydrogen or various chemical groups as defined in the description,

q is 0 to 7;

R₁ represents hydrogen, alkyl, alkenyl, alkynyl, or a ring system,

and optionally, its optical isomers, N-oxide, and addition salts thereof with a pharmaceutically-acceptable acid or base, and medicinal products containing the same are useful as specific inhibitors of type-13 matrix metalloprotease.